Neurotech Advancements: Synchron Boosts Brain Implant Production Through Equity Stake in Acquandas

Synchron’s Brain-Computer Interface (BCI) Gains Momentum with Strategic Partnership and Plans for Commercial Expansion


1. Synchron’s Strategic Move:
– Neurotech startup Synchron is enhancing production of its brain-computer interface (BCI), the Synchron Switch, by securing a minority equity stake in German manufacturer Acquandas. This move aims to meet the rising demand for Synchron’s innovative BCI, positioned to empower individuals with limited physical mobility.

2. Synchron Switch:
– Synchron Switch, resembling a stent, is inserted through blood vessels, enabling individuals with physical limitations to control smart home devices and cursors using their minds. The BCI has undergone initial studies, with implants conducted on patients in the U.S. and Australia.

3. Partnership with Acquandas:
– The partnership grants Synchron exclusive access to Acquandas’ layering technology, a crucial component of the BCI implant. Synchron’s CEO and CTO will join Acquandas’ board, fostering collaboration in innovation and scaling up production.


4. Addressing Unmet Needs:
– Synchron recognizes the significant potential of its BCI technology to benefit millions of paralyzed individuals. The equity stake in Acquandas positions Synchron to address the large unmet need and prepare for high-volume production.

5. Patient Registry Launch:
– Synchron plans to launch an official patient registry in mid-February, facilitating prospective patients with limb or motor impairment to express interest, stay updated on trials, and provide details about their needs. The registry aims to shape the focus on clinical sites across the U.S.

6. Investor Attention and Financing:
– Synchron has garnered attention from influential investors, including Bill Gates’ and Jeff Bezos’ investment firms, securing $75 million in a 2022 financing round. Elon Musk, CEO of Neuralink, has shown interest in Synchron, emphasizing a less-invasive approach compared to Neuralink’s open-brain surgery implantation.

7. Minimally Invasive Approach vs. Neuralink:
– While Neuralink implants directly into brain tissue through open surgery, Synchron’s Stentrode uses an endovascular technique, minimizing invasiveness. Although Synchron’s brain signals may not be as strong, the team believes the less-invasive procedure enhances accessibility.

8. Competitive Landscape:
– Synchron’s strategic positioning and innovative approach draw comparisons with Neuralink. The unique features of each company’s BCI contribute to the evolving landscape of neurotech, sparking interest and competition in the industry.

Synchron’s equity stake in Acquandas and ongoing advancements in its BCI technology position the company to navigate the competitive landscape, addressing unmet needs and preparing for widespread commercialization. Stay informed on the progress of Synchron in the dynamic field of neurotechnology.